PharmaFocus Today – Page 2 – media

Subsidiary’s self-developed Class 1 innovative drug, bemosubalimab injection, in combination therapy, has been approved for marketing.

　　On August 7, China Biopharmaceutical (01177) issued an announcement stating that its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., has independently developed a Class 1 innovative drug.Bemosubalimab injection in combination with chemotherapy followed by anlotinib hydrochloride capsules has been approved for marketing by the National Medical Products Administration of China for first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer. 　　The announcement mentioned that this is the 12th approved indication for anlotinib and the 6th approved indication for bemosubib. https://finance.eastmoney.com/a/202608073835411830.html
- Source: drugdu
- 64
- August 13, 2026
Hanyu Pharmaceutical has licensed 3SBio’s Smegglutide injection to commercialize the product, with sales milestones reaching up to 145 million yuan.

On August 12, Hanyu Pharmaceutical(300199) issued an announcement stating that the company has reached an agreement with Zhejiang Sansheng Mandi Pharmaceutical Co., Ltd., and the two parties have reached a cooperation agreement on the development, registration, production and commercialization of Smegglutide injection (for blood glucose control) in China (excluding Taiwan). The company granted 3SBio an exclusive, non-transferable, and sublicensable license in the region, under which 3SBio or its affiliates shall act as the marketing authorization holder for the collaborative products in China and be solely responsible for the commercialization of the collaborative products in the region. The financial terms of this collaboration consist of three parts: an initial payment to 3SBio for signing the agreement, milestone payments for registration and commercialization, and sales royalties. The initial payment is RMB 12 million. The milestone payments for registration and commercialization include RMB 18 million upon approval of the blood glucose indication for ...
- Source: drugdu
- 64
- August 13, 2026
Is Your Product Ready for Global Markets? Drugdu.com 10th Anniversary Overseas Promotion Readiness Program

Helping pharmaceutical and medical device companies better understand their overseas promotion readiness and next growth opportunities Expanding Overseas Markets Requires More Than Having a Good Product For pharmaceutical and medical device companies, entering global markets involves more than simply listing products online or finding potential buyers. Successful overseas promotion requires companies to present their capabilities clearly, communicate product value effectively, identify suitable markets, and build trust with international buyers. However, many companies still face challenges during their overseas expansion journey: They have strong products and manufacturing capabilities but are unsure which products should be prioritized for global promotion. They already have export experience but need clearer direction on which markets and channels to focus on. They have participated in exhibitions or invested in promotion but lack continuous feedback to optimize future strategies. Before investing more resources, companies need a clearer understanding of their current overseas promotion readiness. Drugdu.com 10th Anniversary ...
- Source: drugdu
- 80
- August 13, 2026
Miraberon API Receives FDA Registration Approval

China Securities Intelligent Finance – Tonghe Pharmaceutical(300636) announced on the evening of August 11 that the company recently received Miraberon API issued by the U.S. Food and Drug Administration.The NFC Letter indicates that the FDA has completed its technical review of the company’s DMF file for the Miraberon active pharmaceutical ingredient , which meets the ANDA application requirements of related formulation customers. The announcement indicates that mirabezone is a selective β3-adrenergic receptor agonist that can improve bladder filling and storage capacity by activating β3-adrenergic receptors on the bladder detrusor muscle. Clinically, it is used to treat overactive bladder with symptoms such as urge incontinence, urgency, and frequency. The company stated that the successful technical review of Mirabelon API will facilitate market expansion and customer acquisition, and will play a positive role in further expanding the company’s international business. https://finance.eastmoney.com/a/202608113837991159.html
- Source: drugdu
- 143
- August 12, 2026
Subsidiary’s 9-valent HPV vaccine receives marketing authorization in Thailand

Shanghai Securities News, China Securities Network, August 11 – Wantai Biopharmaceutical…Disclosure regarding the company’s nine-valent HPV vaccineAnnouncement of Marketing Authorization in Thailand. The announcement states that the nine-valent human papillomavirus vaccine (Escherichia coli) independently developed by the company’s wholly-owned subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd., has recently received approval from the Thai Food and Drug Administration. The nine-valent HPV vaccine is a preventive biological product independently developed by Wantai Biological Pharmacy Enterprise Co., Ltd.This is my country’s first and the world’s second nine-valent HPV vaccine. It is mainly suitable for women aged 9-45 and covers seven high-risk HPV types (16/18/31/33/45/52/58) and two low-risk HPV types (6/11). It can prevent diseases caused by infection with the above-mentioned human papillomavirus types. The company stated that the approval of the 9-valent HPV vaccine in Thailand marks the first overseas marketing authorization for this product, signifying that it is now qualified for export to ...
- Source: drugdu
- 107
- August 12, 2026
Signs Master Collaboration Agreement with Stella Pharma for the Commercialization of Boron Neutron Therapy Drugs

　　On August 12, Nanfang Finance News reported that China Biotechnology Services (08037.HK) issued a voluntary announcement stating that on August 11, 2026, the company entered into a legally binding master collaboration agreement with Stella Pharma Corporation for the development and commercialization in China of Steboronine®, the world’s first approved boron neutron therapy drug. The agreement is divided into two phases: development and commercialization. In the development phase, the company will be the exclusive agent to submit regulatory filings to the National Medical Products Administration (NMPA) to promote NMPA approval of Steboronine® for head and neck cancer and subsequent meningioma indications. In the commercialization phase, Pengbo (Hainan) Boron Neutron Medical Technology Co., Ltd. will act as the exclusive domestic agent, and the company or its designated entity will act as the exclusive general importer/distributor. The initial distribution rights will be valid for ten years after NMPA approval, automatically renewable for five ...
- Source: drugdu
- 85
- August 12, 2026
Medical device giant makes another move in spin-off.

According to recent foreign media reports, Solventum announced plans to spin off its Health Information Systems business as part of its portfolio optimization strategy. Image source: Latest Medical Device News on MassDevice Solventum was spun off from the former 3M healthcare business in 2024, and subsequently announced a massive $120 million restructuring plan in 2025. This spin-off marked the first phase of Solventum’s management’s business transformation strategy, with the goal of “building consensus and strengthening the foundation,” including establishing a new mission of “improving human health with better, smarter, and safer healthcare solutions.” In the second phase, Solventum will focus on strategic in-depth development, with 80% of revenue growth expected to come from five major areas: negative pressure wound therapy, intravenous catheter management, sterilization assurance, basic repair products, and revenue cycle management. This spin-off is the latest step in Solventum’s three-phase transformation strategy, aimed at maximizing shareholder value and preparing ...
- Source: drugdu
- 65
- August 12, 2026
Johnson & Johnson veterans lead the way as ICL giant embarks on its second growth curve.

According to recent foreign media reports, Staar Surgical announced the appointment of Warren Foust as the company’s new president and CEO. Image source: Latest Medical Device News on MassDevice Founded in 1982, Staar Surgical focuses on the ophthalmology sector. According to data from Tidus Medical Devices, the company currently has 75 products on the market in the United States and 5 products on the market in China. Its core product pipeline is the Evo implantable collagen lens (ICL) pipeline. Its newly appointed President and CEO, Foust, joined the company in April 2023 as Chief Operating Officer and will assume the title of President in March 2025. During his tenure at Staar, he was responsible for research and development, global sales, marketing, manufacturing, and operations. The company stated that he led the company to a successful operational restructuring and a return to profitable growth. Foust is a seasoned veteran of the ...
- Source: drugdu
- 68
- August 12, 2026
A Milestone in Pediatric Traditional Chinese Medicine Innovation! Jichuan Pharmaceutical’s Pediatric Laxative Granules Fill a Gap

Recently, Jichuan Pharmaceutical’s independently developed Class 1.1 innovative traditional Chinese medicine, Xiaotongbian Granules ( Pediatric Constipation Relief Granules) , officially received marketing approval from the National Medical Products Administration. This product fills the gap in the domestic market for traditional Chinese medicine specifically for children’s constipation , enriches the company’s product portfolio, and enhances its core competitiveness in the pediatric field. 01 Classic prescriptions from renowned doctors benefit a large number of children suffering from constipation Pediatric Constipation Relief Granules are the first innovative traditional Chinese medicine (TCM) drug approved for use in children under the new regulations and guidelines for innovative TCM drugs. It is the first innovative demonstration product in this field , filling a gap in domestic TCM treatments specifically for childhood constipation. The prescription originates from the clinical experience of pediatric expert Chen Yonghui (Capital Children’s Medical Center, Capital Medical University), and clinical trials have verified ...
- Source: drugdu
- 67
- August 10, 2026
Vonoprazan Fumarate Tablets Receive Drug Registration Certificate

On August 7th, Huahai Pharmaceutical(600521) issued an announcement stating that the company recently received the “Drug Registration Certificate” for vonoprazan fumarate tablets issued by the National Medical Products Administration. The drug is a tablet, with specifications of 20mg and 10mg, and is registered as a Class 4 chemical drug. Vonoprazan fumarate tablets are used for reflux esophagitis and can be used in combination with appropriate antibiotics to eradicate Helicobacter pylori. According to data from Menet.com, the domestic market sales of this drug are projected to reach approximately RMB 282 million in the first quarter of 2026. The company’s R&D investment in the vonoprazan fumarate tablets project is approximately RMB 4.22 million. In the first quarter of 2026, Huahai Pharmaceutical achieved revenue of 2.335 billion yuan and net profit attributable to the parent company of 404 million yuan. https://finance.eastmoney.com/a/202608073835322537.html
- Source: drugdu
- 65
- August 10, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.